Functional Cosmetics Market to Reach USD 5.44 Billion by 2032, Driven by Rising Demand for Natural Ingredients and Regulatory Transparency
SNS Insider Unveils Strategic Insights into the U.S. Functional Cosmetics Market's Robust Growth-Worth USD 965.42 Million in 2024---While North America Dominates 32.7% of Global Market Share During Beauty Innovation Revolution.
Austin, June 10, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, The Functional Cosmetics Market size was valued at USD 3.62 billion in 2024 and is expected to reach USD 5.44 billion by 2032, growing at a CAGR of 5.37% over the forecast period of 2025-2032.
Evolving Consumer Preferences and Regulatory Reforms Fuel Growth in Functional Cosmetics with Emphasis on Safety, Transparency, and Natural Actives
The functional cosmetic industry is expanding on account of people's favoring multi-tasking beauty products and bioactive agents. Regulations, such as the MoCRA 2022, demand transparency and safety of products, thus conferring trust via costumers. The US had USD 43 billion in cosmetics revenue in 2021 and high daily use. There is also growing consumer awareness of the dangers of chemicals and demand for natural concoctions, with 78 per cent of consumers worried about toxic ingredients. Ingredient suppliers are also following FDA GMP standards and the integrity and innovation of the market is increasing.Get a Sample Report of Functional Cosmetics Market@ https://www.snsinsider.com/sample-request/7219
The U.S. functional cosmetics market is worth USD 965.42 million in 2024, and will grow at a CAGR of 4.84% in 2025-2032.
Growth in the US functional beauty market is being fuelled by demands for MoCRA certification, increasing skin-health consciousness, and a recently found thirst for innovative US companies, such as Beautycounter and Drunk Elephant, where active-rich natural formulas and strict ingredient-transparency criteria are front of mind.
Major Players Analysis Listed in this Report are:
L'Oréal S.A.
The Estée Lauder Companies Inc.
Procter & Gamble Co.
Unilever PLC
Shiseido Company Limited
Beiersdorf AG
Kenvue Inc. (formerly Johnson & Johnson Consumer)
Amorepacific Corporation
Kao Corporation
Colgate-Palmolive Company
Functional Cosmetics Market Report Scope
Report Attributes
Details
Market Size in 2024
US$ 3.62 billion
Market Size by 2032
US$ 5.44 billion
CAGR
CAGR of 5.23% From 2025 to 2032
Base Year
2024
Forecast Period
2025-2032
Historical Data
2021-2023
Regional Analysis
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Segment Analysis
By Type, Natural Ingredients dominated the Functional Cosmetics Market in 2024 with a 53.8% Market Share.
The natural-type segment dominated in 2023 as consumers looked for natural plant-based actives such as ceramides and hyaluronic acid instead of synthetic chemical ingredients. The growing influence of the FDA on harmful additives, along with increasing trust in natural ingredients, drove the segment growth, with botanical extracts being increasingly popular for their clinically proven advantages. This convergence of consumer demand and government backing has established natural materials as the key ingredients in functional cosmetics.
By Application, Alpha Hydroxy Acids (AHAs) dominated the Functional Cosmetics Market in 2024 with a 22.5% Market Share.
In 2023, Alpha Hydroxy Acids (AHAs) dominated the product-type segment with their ability to exfoliate, hydrate, and combat aging. Brands such as The Ordinary and Neutrogena have AHA products, making them more trusted by consumers. Growth has been fueled by endorsements from dermatology associations and rising US product launches. Evidence-led results and a wide range of usage in skin care routines have made AHAs preferred elements in functional cosmetics.
By Form, Creams & Lotions dominated the Functional Cosmetics Market in 2024 with a 38.5% Market Share.
In 2023, the creams and lotions dominated because of their hydrating feel, quick spreading properties, and ability to target the delivery of multiple actives. Brands such as CeraVe, Olay, and Clinique market products with ceramides and hyaluronic acid tailored to different skin types. Endorsements from dermatology associations and the availability of tele-dermatology kits for particular skin requirements have also added to their ascendance in the functional cosmetics sector.
For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ https://www.snsinsider.com/request-analyst/7219
Functional Cosmetics Market Segmentation
By Type
Natural
Synthetic
By Product Type
Alpha Hydroxy Acids (AHAs)
Polyhydroxy Acids
Beta Hydroxy Acid (Salicylic Acid)
Hydroquinone
Kojic Acid
Retinoid
L-Ascorbic Acid
Others
By Form
Cream & Lotion
Gel
Mask
Powders
Serums
By Functionality
Conditioning Agents
UV Filters
Anti-Ageing Agents
Skin-Lightening Agents
Others
By Application
Skin Care
Hair Care
By End-user
Male
Female
By Distribution Channel
Online
Brand Websites
E-Commerce Websites
Offline
Departmental Stores
Drugstores/Pharmacies
Specialty Stores
By Region, North America dominated the Functional Cosmetics Market in 2024, Holding A 32.7% Market Share.
North America dominated the Functional Cosmetics Market in 2023 owing to early regulatory adoption, high skincare spending, and innovation by major players including Estée Lauder and P&G. The efforts to verify ingredients by FDA and GAO built trust and strengthened stakeholders' collaboration among the different agencies, academia, and start-ups, and consequently accelerated the adoption of the new actives. Additionally, North America had robust e-commerce and telehealth platforms that further facilitated access to the products.
Recent Development
In May 2025, Shin-Etsu Chemical launched four new silicone ingredients to enhance cosmetic texture, hydration, and microplastic-free soft-focus effects.
Buy a Single-User PDF of Functional Cosmetics Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/7219
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Functional Cosmetics Market by Type
8. Functional Cosmetics Market by Product Type
9. Functional Cosmetics Market by Form
10. Functional Cosmetics Market by Functionality
11. Functional Cosmetics Market by Application
12. Functional Cosmetics Market by End-user
13. Functional Cosmetics Market by Distribution Channel
14. Regional Analysis
15. Company Profiles
16. Use Cases and Best Practices
17. Conclusion
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: info@snsinsider.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports First Quarter Results
ATLANTA, June 11, 2025 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its first quarter of fiscal 2025 ended May 3, 2025. Consolidated net sales in the first quarter of fiscal 2025 were $393 million compared to $398 million in the first quarter of fiscal 2024. EPS on a GAAP basis was $1.70 compared to $2.42 in the first quarter of fiscal 2024. On an adjusted basis, EPS was $1.82 compared to $2.66 in the first quarter of fiscal 2024. Tom Chubb, Chairman and CEO, commented, 'We were able to deliver sales and adjusted EPS within our guidance ranges for the first quarter despite uncertain tariff and trade dynamics that are significantly impacting our industry and operating landscape. Despite the increasing headwinds, we were led by a low double digit increase at Lilly Pulitzer as the brand's current assortment is resonating strongly with its core consumer, and overall sales were only modestly lower than last year. At the same time, we were able to maintain strong gross margins above 64%." Mr. Chubb concluded, 'I am proud of the way the teams across our Company have responded swiftly to rapidly changing trade and tariff developments. Our teams have made meaningful progress in diversifying and shifting our supply chain to reduce our exposure to future tariff developments. We believe that our portfolio of differentiated lifestyle brands and strong balance sheet will enable us to navigate this uncertain period, manage the business to drive long-term shareholder value and provide an opportunity to gain market share in the current environment. We will continue to focus on what we can control, including executing our strategy and servicing our customers.' First Quarter of Fiscal 2025 versus Fiscal 2024 Net Sales by Operating Group First Quarter ($ in millions) 2025 2024 % Change Tommy Bahama $ 216.2 $ 225.6 (4.2 %) Lilly Pulitzer 99.0 88.4 12.0 % Johnny Was 43.5 51.2 (15.1 %) Emerging Brands 34.2 33.0 3.8 % Other (0.1 ) (0.1 ) NM Total Company $ 392.9 $ 398.2 (1.3 %) Consolidated net sales of $393 million decreased compared to sales of $398 million in the first quarter of fiscal 2024. Full-price direct-to-consumer (DTC) sales decreased 3% to $249 million versus the first quarter of fiscal 2024. Full-price retail sales of $135 million were 1% lower than the prior-year period. E-commerce sales of $114 million were 5% lower than the prior-year period. Outlet sales of $18 million were comparable to the prior period. Food and beverage sales were $34 million, a 3% decrease versus the prior-year period. Wholesale sales increased 4% to $92 million versus the first quarter of fiscal 2024. Gross margin was 64.2% on a GAAP basis, compared to 64.9% in the first quarter of fiscal 2024. On an adjusted basis, gross margin was 64.3% compared to 65.4% in the first quarter of fiscal 2024. The decreased gross margin on a GAAP basis was primarily due to (1) increased freight expenses to e-commerce customers at Tommy Bahama, (2) increased markdowns during clearance events at Lilly Pulitzer and Johnny Was and (3) a change in sales mix with wholesale sales, including off-priced wholesale sales, representing a higher proportion of net sales. We also incurred $1 million of additional charges in cost of goods sold in the first quarter of fiscal 2025 resulting from the U.S. tariffs on imported goods implemented in the first quarter of fiscal 2025. These decreases were partially offset by a $2 million lower LIFO accounting charge in the first quarter of fiscal 2025 compared to the first quarter of fiscal 2024. SG&A was $223 million compared to $213 million last year with approximately $6 million, or 59%, of the increase is related to increases in employment costs, occupancy costs and depreciation expense due to the opening of 31 new brick and mortar retail locations since the first quarter of fiscal 2024. This includes the 8 net new stores including 2 Tommy Bahama Marlin Bars opened in the first quarter of fiscal 2025. We also incurred pre-opening expenses related to some of the approximately 7 additional stores planned to open during the remainder of fiscal 2025, including an additional Tommy Bahama Marlin Bar. On an adjusted basis, SG&A was $221 million compared to $210 million in the prior-year period. Royalties and other operating income decreased $1 million to $7 million in the first quarter of fiscal 2025 primarily due to decreased royalty income in Tommy Bahama reflecting the lower sales of our licensing partners. Operating income was $36 million, or 9.2% of net sales, compared to $52 million, or 13.2% of net sales, in the first quarter of fiscal 2024. On an adjusted basis, operating income decreased to $39 million, or 9.8% of net sales, compared to $57 million, or 14.4% of net sales, in the first quarter of fiscal 2024. Interest expense increased to $2 million from $1 million in the prior year period. The increased interest expense was primarily due to a higher average outstanding debt balance during the first quarter of fiscal 2025 than the first quarter of fiscal 2024. The effective income tax rate in the first quarter of fiscal 2025 was 24.1% which primarily reflects the benefit derived from a reduction in income tax expense as a result of the receipt of interest from a U.S. federal income tax receivable and the remeasurement of deferred tax balances due to changes in state tax rates partially offset by a net increase to uncertain tax positions during the quarter. The effective tax rate in the first quarter of fiscal 2024 was 25.6% which primarily reflects the unfavorable remeasurement of deferred tax assets and an increase to uncertain tax positions partially offset by a favorable return-to-provision adjustment for a foreign subsidiary. Balance Sheet and Liquidity Inventory increased $18 million, or 12%, on a LIFO basis and $20 million, or 9%, on a FIFO basis compared to the end of the first quarter of fiscal 2024. Inventories increased in all operating segments with the exception of Johnny Was due primarily to impacts associated with the U.S. tariffs that were implemented in first quarter of fiscal 2025 including (1) accelerated purchases of inventory before the anticipated implementation of increased tariffs and (2) increased costs capitalized into inventory after the implementation of the tariffs. At the end of the first quarter of fiscal 2025, our inventory balances included an additional $3 million of costs associated with the increased tariffs implemented in the first quarter of fiscal 2025. During the first quarter of fiscal 2025, cash used in operations was $4 million compared to cash provided by operations of $33 million in the first quarter of fiscal 2024. The cash used in operations reflects the result of lower net earnings, working capital needs, including accelerating inventory purchases, and $12 million of capitalizable implementation costs associated with cloud computing arrangements. Borrowings outstanding increased to $118 million at the end of the first quarter of fiscal 2025 compared to $19 million and $31 million of borrowings outstanding at the end of the first quarter of fiscal 2024 and the fourth quarter of fiscal 2024, respectively. During the first quarter of fiscal 2025, share repurchases of $51 million, capital expenditures of $23 million primarily associated with the project to build a new distribution center in Lyons, Georgia, and the opening of eight new stores, including two Tommy Bahama Marlin Bars, $12 million of capitalizable implementation costs associated with cloud computing arrangements, dividend payments of $10 million, and working capital requirements exceeded cash flow from operations. The Company had $8 million of cash and cash equivalents at the end of both the first quarter of fiscal 2025 and the first quarter of fiscal 2024. Dividend The Board of Directors declared a quarterly cash dividend of $0.69 per share. The dividend is payable on August 1, 2025 to shareholders of record as of the close of business on July 18, 2025. The Company has paid dividends every quarter since it became publicly owned in 1960. Outlook For fiscal 2025 ending on January 31, 2026, the Company revised its sales and EPS guidance. The Company now expects net sales in a range of $1.475 billion to $1.515 billion as compared to net sales of $1.52 billion in fiscal 2024. In fiscal 2025, GAAP EPS is expected to be between $2.28 and $2.68 compared to fiscal 2024 GAAP EPS of $5.87. Adjusted EPS is expected to be between $2.80 and $3.20, compared to fiscal 2024 adjusted EPS of $6.68. The revised fiscal 2025 EPS and adjusted EPS guidance includes $40 million in additional tariff costs, or $2.00 per share on an after-tax basis. For the second quarter of fiscal 2025, the Company expects net sales to be between $395 million and $415 million compared to net sales of $420 million in the second quarter of fiscal 2024. GAAP EPS is expected to be between $0.92 and $1.12 in the second quarter of fiscal 2025 compared to a GAAP EPS of $2.57 in the second quarter of fiscal 2024. Adjusted EPS is expected to be between $1.05 and $1.25 compared to adjusted EPS of $2.77 in the second quarter of fiscal 2024. The revised second quarter of fiscal 2025 EPS guidance includes $15 million in additional tariff costs, or $0.75 per share on an after-tax basis. The Company anticipates interest expense of $8 million in fiscal 2025, with interest expense expected to be between $1 million and $2 million per quarter for the remainder of fiscal 2025. The Company's effective tax rate is expected to be approximately 26% for the full year of fiscal 2025. Capital expenditures in fiscal 2025, including the $23 million in the first quarter of fiscal 2025, are expected to be approximately $120 million compared to $134 million in fiscal 2024. The planned year-over-year decrease relates primarily to lower anticipated new store openings in fiscal 2025. The Company expects a year-over-year net increase of approximately 15 full price stores by the end of fiscal 2025, including three new Marlin Bars. The $120 million in expected capital expenditures in fiscal 2025 includes capital expenditures of approximately $70 million related to the completion of the project to build a new distribution center in Lyons, Georgia, including $10 million in the first quarter of fiscal 2025, and capital expenditures related to new stores and Tommy Bahama Marlin Bars. Conference Call The Company will hold a conference call with senior management to discuss its financial results at 4:30 p.m. ET today. A live web cast of the conference call will be available on the Company's website at A replay of the call will be available through June 25, 2025 by dialing (412) 317-6671 access code 13753975. About Oxford Oxford Industries, Inc., a leader in the apparel industry, owns and markets the distinctive Tommy Bahama®, Lilly Pulitzer®, Johnny Was®, Southern Tide®, The Beaufort Bonnet Company®, Duck Head® and Jack Rogers® lifestyle brands. Oxford's stock has traded on the New York Stock Exchange since 1964 under the symbol OXM. For more information, please visit Oxford's website at Basis of Presentation All per share information is presented on a diluted basis. Non-GAAP Financial Information The Company reports its consolidated financial statements in accordance with generally accepted accounting principles (GAAP). To supplement these consolidated financial results, management believes that a presentation and discussion of certain financial measures on an adjusted basis, which exclude certain non-operating or discrete gains, charges or other items, may provide a more meaningful basis on which investors may compare the Company's ongoing results of operations between periods. These measures include net adjusted earnings, adjusted net earnings per share, adjusted gross profit, adjusted gross margin, adjusted SG&A, and adjusted operating income, among others. Management uses these non-GAAP financial measures in making financial, operational, and planning decisions to evaluate the Company's ongoing performance. Management also uses these adjusted financial measures to discuss its business with investment and other financial institutions, its board of directors and others. Reconciliations of these adjusted measures to the most directly comparable financial measures calculated in accordance with GAAP are presented in tables included at the end of this release. Safe Harbor This press release includes statements that constitute forward-looking statements within the meaning of the federal securities laws. Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. We intend for all forward-looking statements contained herein, in our press releases or on our website, and all subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf, to be covered by the safe harbor provisions for forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Such statements are subject to a number of risks, uncertainties and assumptions including, without limitation: changes in the trade policies of the United States and those of other nations, including risks of potential future changes or worsening trade tensions between the United States and other countries and the impact of uncertainties surrounding U.S. trade policy on consumer sentiment; demand for our products, which may be impacted by macroeconomic factors that may impact consumer discretionary spending and pricing levels for apparel and related products, many of which may be impacted by inflationary pressures, tariffs, volatile and/or elevated interest rates, concerns about a potential global recession, the stability of the banking industry or general economic uncertainty, and the effectiveness of measures to mitigate the impact of these factors; risks relating to our product sourcing decentralization efforts, including our ability to identify alternative countries to source and produce our products and to successfully implement changes in our supply chain; possible changes in governmental monetary and fiscal policies, including, but not limited to, Federal Reserve policies in connection with continued inflationary pressures; competitive conditions and/or evolving consumer shopping patterns, particularly in a highly promotional retail environment; acquisition activities (such as the acquisition of Johnny Was); global supply chain constraints that have, and could continue, to affect freight, transit, and other costs; costs and availability of labor and freight deliveries, including our ability to appropriately staff our retail stores and food & beverage locations; costs of products as well as the raw materials used in those products, as well as our ability to pass along price increases to consumers; energy costs; our ability to respond to rapidly changing consumer expectations; unseasonal or extreme weather conditions or natural disasters, such as the 2024 hurricanes impacting the Southeastern United States; lack of or insufficient insurance coverage; the ability of business partners, including suppliers, vendors, wholesale customers, licensees, logistics providers and landlords, to meet their obligations to us and/or continue our business relationship to the same degree as they have historically; hiring of, retention of and disciplined execution by key management and other critical personnel; cybersecurity breaches and ransomware attacks, as well as our and our third party vendors' ability to properly collect, use, manage and secure business, consumer and employee data and maintain continuity of our information technology systems; the effectiveness of our advertising initiatives in defining, launching and communicating brand-relevant customer experiences; the level of our indebtedness, including the risks associated with heightened interest rates on the debt and the potential impact on our ability to operate and expand our business; the timing of shipments requested by our wholesale customers; fluctuations and volatility in global financial and/or real estate markets; our ability to identify and secure suitable locations for new retail store and food & beverage openings; the timing and cost of retail store and food & beverage location openings and remodels, technology implementations and other capital expenditures; the timing, cost and successful implementation of changes to our distribution network; the effectiveness of recent, focused efforts to reassess and realign our operating costs in light of revenue trends, including potential disruptions to our operations as a result of these efforts; pandemics or other public health crises; expected outcomes of pending or potential litigation and regulatory actions; consumer, employee and regulatory focus on sustainability issues and practices, including failures by our suppliers to adhere to our vendor code of conduct; the regulation or prohibition of goods sourced, or containing raw materials or components, from certain regions and our ability to evidence compliance; access to capital and/or credit markets; factors that could affect our consolidated effective tax rate, including the impact of potential changes in U.S. tax laws and regulations; the risk of impairment to goodwill and other intangible assets such as the recent impairment charges incurred in our Johnny Was segment; and geopolitical risks, including ongoing challenges between the United States and China and those related to the ongoing war in Ukraine, the Israel-Hamas war and the conflict in the Red Sea region. Forward-looking statements reflect our expectations at the time such forward-looking statements are made, based on information available at such time, and are not guarantees of performance. Although we believe that the expectations reflected in such forward-looking statements are reasonable, these expectations could prove inaccurate as such statements involve risks and uncertainties, many of which are beyond our ability to control or predict. Should one or more of these risks or uncertainties, or other risks or uncertainties not currently known to us or that we currently deem to be immaterial, materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. Important factors relating to these risks and uncertainties include, but are not limited to, those described in Part I. Item 1A. Risk Factors contained in our Fiscal 2024 Form 10-K, and those described from time to time in our future reports filed with the SEC. We caution that one should not place undue reliance on forward-looking statements, which speak only as of the date on which they are made. We disclaim any intention, obligation or duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact:E-mail: Brian SmithInvestorRelations@ Industries, Inc. Consolidated Balance Sheets (in thousands, except par amounts) (unaudited) May 3, May 4, 2025 2024 ASSETS Current Assets Cash and cash equivalents $ 8,175 $ 7,657 Receivables, net 105,501 87,918 Inventories, net 162,334 144,373 Income tax receivable 271 19,437 Prepaid expenses and other current assets 41,253 38,978 Total Current Assets $ 317,534 $ 298,363 Property and equipment, net 281,504 193,702 Intangible assets, net 255,768 259,147 Goodwill 27,403 27,185 Operating lease assets 372,452 319,308 Other assets, net 63,195 41,183 Deferred income taxes 21,850 18,088 Total Assets $ 1,339,706 $ 1,156,976 LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities Accounts payable $ 86,212 $ 73,755 Accrued compensation 21,417 19,340 Current portion of operating lease liabilities 64,119 65,366 Accrued expenses and other liabilities 69,007 67,124 Total Current Liabilities $ 240,755 $ 225,585 Long-term debt 117,714 18,630 Non-current portion of operating lease liabilities 360,935 296,080 Other non-current liabilities 27,879 23,806 Shareholders' Equity Common stock, $1.00 par value per share 14,875 15,634 Additional paid-in capital 194,893 183,126 Retained earnings 385,761 396,933 Accumulated other comprehensive loss (3,106 ) (2,818 ) Total Shareholders' Equity $ 592,423 $ 592,875 Total Liabilities and Shareholders' Equity $ 1,339,706 $ 1,156,976Oxford Industries, Inc. Consolidated Statements of Operations (in thousands, except per share amounts) (unaudited) First Quarter Fiscal 2025 Fiscal 2024 Net sales $ 392,861 $ 398,184 Cost of goods sold 140,575 139,823 Gross profit $ 252,286 $ 258,361 SG&A 222,708 213,103 Royalties and other operating income 6,628 7,193 Operating income $ 36,206 $ 52,451 Interest expense, net 1,726 874 Earnings before income taxes $ 34,480 $ 51,577 Income tax expense 8,299 13,204 Net earnings $ 26,181 $ 38,373 Net earnings per share: Basic $ 1.72 $ 2.46 Diluted $ 1.70 $ 2.42 Weighted average shares outstanding: Basic 15,222 15,597 Diluted 15,404 15,844 Dividends declared per share $ 0.69 $ 0.67Oxford Industries, Inc. Consolidated Statements of Cash Flows (in thousands) (unaudited) First Quarter Fiscal 2025 Fiscal 2024 Cash Flows From Operating Activities: Net earnings $ 26,181 $ 38,373 Adjustments to reconcile net earnings to cash flows from operating activities: Depreciation 14,529 13,586 Amortization of intangible assets 2,434 2,955 Equity compensation expense 3,605 4,051 Amortization and write-off of deferred financing costs 96 96 Deferred income taxes (1,440 ) 6,059 Changes in operating assets and liabilities, net of acquisitions and dispositions: Receivables, net (33,078 ) (24,571 ) Inventories, net 5,271 15,151 Income tax receivable 5,053 112 Prepaid expenses and other current assets (2,973 ) 4,051 Current liabilities (7,376 ) (15,365 ) Other balance sheet changes (16,244 ) (11,575 ) Cash (used in) provided by operating activities $ (3,942 ) $ 32,923 Cash Flows From Investing Activities: Acquisitions, net of cash acquired (28 ) (240 ) Purchases of property and equipment (23,427 ) (11,894 ) Cash used in investing activities $ (23,455 ) $ (12,134 ) Cash Flows From Financing Activities: Repayment of revolving credit arrangements (94,125 ) (136,216 ) Proceeds from revolving credit arrangements 180,733 125,542 Repurchase of common stock (50,526 ) — Proceeds from issuance of common stock 482 513 Cash dividends paid (10,381 ) (10,549 ) Other financing activities (224 ) — Cash provided by (used in) financing activities $ 25,959 $ (20,710 ) Net change in cash and cash equivalents (1,438 ) 79 Effect of foreign currency translation on cash and cash equivalents 143 (26 ) Cash and cash equivalents at the beginning of year 9,470 7,604 Cash and cash equivalents at the end of period $ 8,175 $ 7,657Oxford Industries, Inc. Reconciliations of Certain Non-GAAP Financial Information (in millions, except per share amounts) (unaudited) First Quarter AS REPORTED Fiscal 2025 Fiscal 2024 % Change Tommy Bahama Net sales $ 216.2 $ 225.6 (4.2 )% Gross profit $ 139.7 $ 148.3 (5.8 )% Gross margin 64.6 % 65.7 % Operating income $ 30.7 $ 42.6 (27.9 )% Operating margin 14.2 % 18.9 % Lilly Pulitzer Net sales $ 99.0 $ 88.4 12.0 % Gross profit $ 64.9 $ 59.3 9.5 % Gross margin 65.6 % 67.0 % Operating income $ 18.1 $ 15.5 16.7 % Operating margin 18.3 % 17.6 % Johnny Was Net sales $ 43.5 $ 51.2 (15.1 )% Gross profit $ 28.1 $ 33.2 (15.4 )% Gross margin 64.7 % 64.9 % Operating (loss) income $ (3.4 ) $ 0.3 (1124.0 )% Operating margin (7.8 )% 0.7 % Emerging Brands Net sales $ 34.2 $ 33.0 3.8 % Gross profit $ 20.3 $ 19.5 4.0 % Gross margin 59.3 % 59.2 % Operating income $ 1.9 $ 3.8 (49.8 )% Operating margin 5.6 % 11.5 % Corporate and Other Net sales $ (0.1 ) $ (0.1 ) NM Gross profit $ (0.8 ) $ (2.0 ) NM Operating loss $ (11.2 ) $ (9.9 ) NM Consolidated Net sales $ 392.9 $ 398.2 (1.3 )% Gross profit $ 252.3 $ 258.4 (2.4 )% Gross margin 64.2 % 64.9 % SG&A $ 222.7 $ 213.1 4.5 % SG&A as % of net sales 56.7 % 53.5 % Operating income $ 36.2 $ 52.5 (31.0 )% Operating margin 9.2 % 13.2 % Earnings before income taxes $ 34.5 $ 51.6 (33.1 )% Net earnings $ 26.2 $ 38.4 (31.8 )% Net earnings per diluted share $ 1.70 $ 2.42 (29.8 )% Weighted average shares outstanding - diluted 15.4 15.8 (2.8 )%First Quarter ADJUSTMENTS Fiscal 2025 Fiscal 2024 % Change LIFO adjustments(1) $ 0.5 $ 2.2 Amortization of Johnny Was intangible assets(2) $ 1.9 $ 2.7 Impact of income taxes(3) $ (0.6 ) $ (1.3 ) Adjustment to net earnings(4) $ 1.8 $ 3.7 AS ADJUSTED Tommy Bahama Net sales $ 216.2 $ 225.6 (4.2 )% Gross profit $ 139.7 $ 148.3 (5.8 )% Gross margin 64.6 % 65.7 % Operating income $ 30.7 $ 42.6 (27.9 )% Operating margin 14.2 % 18.9 % Lilly Pulitzer Net sales $ 99.0 $ 88.4 12.0 % Gross profit $ 64.9 $ 59.3 9.5 % Gross margin 65.6 % 67.0 % Operating income $ 18.1 $ 15.5 16.7 % Operating margin 18.3 % 17.6 % Johnny Was Net sales $ 43.5 $ 51.2 (15.1 )% Gross profit $ 28.1 $ 33.2 (15.4 )% Gross margin 64.7 % 64.9 % Operating (loss) income $ (1.5 ) $ 3.1 (148.4 )% Operating margin (3.4 )% 6.0 % Emerging Brands Net sales $ 34.2 $ 33.0 3.8 % Gross profit $ 20.3 $ 19.5 4.0 % Gross margin 59.3 % 59.2 % Operating income $ 1.9 $ 3.8 (49.8 )% Operating margin 5.6 % 11.5 % Corporate and Other Net sales $ (0.1 ) $ (0.1 ) NM Gross profit $ (0.3 ) $ 0.2 NM Operating loss $ (10.7 ) $ (7.6 ) NM Consolidated Net sales $ 392.9 $ 398.2 (1.3 )% Gross profit $ 252.8 $ 260.6 (3.0 )% Gross margin 64.3 % 65.4 % SG&A $ 220.8 $ 210.4 4.9 % SG&A as % of net sales 56.2 % 52.8 % Operating income $ 38.6 $ 57.4 (32.8 )% Operating margin 9.8 % 14.4 % Earnings before income taxes $ 36.9 $ 56.5 (34.8 )% Net earnings $ 28.0 $ 42.1 (33.5 )% Net earnings per diluted share $ 1.82 $ 2.66 (31.6 )%First Quarter First Quarter First Quarter Fiscal 2025 Fiscal 2025 Fiscal 2024 Actual Guidance(5) Actual Net earnings per diluted share: GAAP basis $ 1.70 $ 1.61 - 1.81 $ 2.42 LIFO adjustments(1)(6) 0.02 0.00 0.11 Amortization of Johnny Was intangible assets(2)(6) 0.09 0.09 0.13 As adjusted(4) $ 1.82 $ $1.70 - $1.90 $ 2.66 Second Quarter Second Quarter Fiscal 2025 Fiscal 2024 Guidance(7) Actual Net earnings per diluted share: GAAP basis $ 0.92 - 1.12 $ 2.57 LIFO adjustments(8) 0.00 0.03 Amortization of Johnny Was intangible assets(2)(6) 0.13 0.13 Johnny Was distribution center relocation costs(9)(6) 0.00 0.04 As adjusted(4) $ 1.05 - 1.25 $ 2.77 Fiscal 2025 Fiscal 2024 Guidance(7) Actual Net earnings per diluted share: GAAP basis $ 2.28 - 2.68 $ 5.87 LIFO adjustments(8) 0.02 0.16 Amortization of Johnny Was intangible assets(2)(6) 0.50 0.51 Johnny Was distribution center relocation costs(9)(6) 0.00 0.14 As adjusted(4) $ 2.80 - 3.20 $ 6.68 (1) LIFO adjustments represents the impact of LIFO accounting adjustments. These adjustments are included in cost of goods sold in Corporate and Other.(2) Amortization of Johnny Was intangible assets represents the amortization related to intangible assets acquired as part of the Johnny Was acquisition. These charges are included in SG&A in Johnny Was.(3) Impact of income taxes represents the estimated tax impact of the above adjustments based on the estimated applicable tax rate on current year earnings.(4) Amounts in columns may not add due to rounding.(5) Guidance as issued on March 27, 2025.(6) Adjustments shown net of income taxes.(7) Guidance as issued on June 11, 2025.(8) No estimate for LIFO accounting adjustments is reflected in the guidance for any future periods.(9) Johnny Was distribution center relocation costs relate to the transition of Johnny Was distribution center operations from Los Angeles, California to Lyons, Georgia including systems integrations, employee bonuses and severance agreements, moving costs and occupancy expenses related to the vacated distribution centers. These charges are included in SG&A in Johnny Was. Direct to Consumer Location Count End of Q1 End of Q2 End of Q3 End of Q4 Fiscal 2024 Tommy Bahama Full-price retail store 102 103 106 106 Retail-food & beverage 23 23 25 24 Outlet 35 36 37 36 Total Tommy Bahama 160 162 168 166 Lilly Pulitzer full-price retail store 60 60 61 64 Johnny Was Full-price retail store 75 76 77 77 Outlet 3 3 3 3 Total Johnny Was 78 79 80 80 Emerging Brands Southern Tide full-price retail store 20 24 28 30 TBBC full-price retail store 4 5 5 5 Total Oxford 322 330 342 345 Fiscal 2025 Tommy Bahama Full-price retail store 103 Retail-food & beverage 26 Outlet 36 Total Tommy Bahama 165 Lilly Pulitzer full-price retail store 65 Johnny Was Full-price retail store 77 Outlet 3 Total Johnny Was 80 Emerging Brands Southern Tide full-price retail store 35 TBBC full-price retail store 8 Total Oxford 353Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Applied Optoelectronics Announces First Volume Shipment of Data Center Transceivers to Recently Engaged Major Hyperscale Customer
SUGAR LAND, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Applied Optoelectronics, Inc. ('AOI') (Nasdaq: AAOI), a leading provider of fiber-optic access network products for the internet datacenter, cable broadband, telecom and fiber-to-the-home (FTTH) markets, today announced the first volume shipment of high-speed data center transceivers to a recently re-engaged major hyperscale data center customer. This milestone is the first volume shipment of these advanced high-speed data center transceivers to this customer, and the first shipment of significant quantity to this customer in several years. 'Throughout the year, we have been expecting growth in data center transceiver sales, particularly in the second half of the year,' commented Dr. Thompson Lin, AOI's Founder, Chairman, and CEO. 'This first volume shipment to this customer represents a significant milestone on a journey to what we continue to expect to be significant business opportunities with this newly re-engaged customer. As we execute on our previously-announced US-based capacity expansion plan, we continue to expect shipments to this customer and other customers to increase in line with our previous commentary of a second-half ramp.' For more information about AOI's industry-leading line of advanced optical transceivers for AI-focused data centers, please refer to the information on AOI's website at About Applied Optoelectronics, Inc. Applied Optoelectronics, Inc. (AOI) is a leading developer and manufacturer of advanced optical products, including components, modules and equipment. AOI's products are the building blocks for broadband fiber access networks around the world, where they are used in the internet datacenter, CATV broadband, telecom and FTTH markets. AOI supplies optical networking lasers, components and equipment to tier-1 customers in all four of these markets. In addition to its corporate headquarters, wafer fab and advanced engineering and production facilities in Sugar Land, TX, AOI has engineering and manufacturing facilities in Taipei, Taiwan and Ningbo, China. For additional information, visit Forward-Looking InformationThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "could," "would," "target," "seek," "aim," "predicts," "think," "objectives," "optimistic," "new," "goal," "strategy," "potential," "is likely," "will," "expect," "plan," "project," "permit" or by other similar expressions that convey uncertainty of future events or outcomes. These statements include management's beliefs and expectations related to our outlook for the second quarter of 2025 and the remainder of 2025. Such forward-looking statements reflect the views of management at the time such statements are made. These forward-looking statements involve risks and uncertainties, as well as assumptions and current expectations, which could cause the company's actual results to differ materially from those anticipated in such forward-looking statements. These risks and uncertainties include but are not limited to: reduction in the size or quantity of customer orders; change in demand for the company's products due to industry conditions; changes in manufacturing operations; volatility in manufacturing costs; delays in shipments of products; disruptions in the supply chain; change in the rate of design wins or the rate of customer acceptance of new products; the company's reliance on a small number of customers for a substantial portion of its revenues; potential pricing pressure; a decline in demand for our customers' products or their rate of deployment of their products; general conditions in the internet datacenter, cable television (CATV) broadband, telecom, or fiber-to-the-home (FTTH) markets; changes in the world economy (particularly in the United States and China); changes in the regulation and taxation of international trade, including the imposition of tariffs; changes in currency exchange rates; the negative effects of seasonality; and other risks and uncertainties described more fully in the company's documents filed with or furnished to the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. More information about these and other risks that may impact the company's business are set forth in the "Risk Factors" section of the company's quarterly and annual reports on file with the Securities and Exchange Commission. You should not rely on forward-looking statements as predictions of future events. All forward-looking statements in this press release are based upon information available to us as of the date hereof, and qualified in their entirety by this cautionary statement. Except as required by law, we assume no obligation to update forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in the company's expectations. Investor Relations Contact: The Blueshirt Group, Investor Relations Lindsay Savarese +1-212-331-8417ir@ in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. 'It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon,' said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. Dr. Mazumdar is the founding Chief Executive Officer of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company. Prior to Bicara, Dr. Mazumdar led business development and corporate strategy at Rheos Medicines, where she supported the precision medicine company's global partnership with Roche Pharmaceuticals. Earlier in her career, she held a position at Third Rock Ventures, where she focused on company formation and business development. She holds a B.S. in biological engineering from the Massachusetts Institute of Technology and earned both an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or follow us on Twitter. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection; the expected benefits resulting from the implementation of the cost saving measures and potential ability to fund key value drivers; and the expectations regarding Relay Therapeutics' use of capital and expenses. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: Relay Therapeutics' restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; the timing, execution, and expected impact of Relay Therapeutics' restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; the expected sufficiency of Relay Therapeutics' existing cash resources; the internal and external costs required for Relay Therapeutics' ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Relay Therapeutics' plans or both; the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade, or regulatory developments, such as tariffs, beyond Relay Therapeutics' control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact:Pete Rahmerprahmer@ Media:Dan Budwick1AB973-271-6085dan@
